CA2416538A1 - Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese - Google Patents

Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese Download PDF

Info

Publication number
CA2416538A1
CA2416538A1 CA002416538A CA2416538A CA2416538A1 CA 2416538 A1 CA2416538 A1 CA 2416538A1 CA 002416538 A CA002416538 A CA 002416538A CA 2416538 A CA2416538 A CA 2416538A CA 2416538 A1 CA2416538 A1 CA 2416538A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
amino acid
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002416538A
Other languages
English (en)
Inventor
Kevin P. Baker
Napoleone Ferrara
Hanspeter Gerber
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Kenneth J. Hillan
Scot A. Marsters
James Pan
Nicholas F. Paoni
Jean-Philippe F. Stephan
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Weilan Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from US09/643,657 external-priority patent/US6642024B1/en
Priority claimed from PCT/US2000/023522 external-priority patent/WO2001016319A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Priority claimed from US09/747,259 external-priority patent/US6569645B2/en
Priority claimed from US09/767,609 external-priority patent/US20020042367A1/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/fr
Priority claimed from PCT/US2001/006666 external-priority patent/WO2001066740A2/fr
Priority claimed from US09/816,744 external-priority patent/US6579520B2/en
Priority claimed from US09/828,366 external-priority patent/US20020010137A1/en
Priority claimed from US09/854,208 external-priority patent/US7217412B2/en
Priority claimed from US09/866,028 external-priority patent/US6642360B2/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/fr
Priority claimed from US09/866,034 external-priority patent/US20030170864A1/en
Priority claimed from US09/870,574 external-priority patent/US6551799B2/en
Priority claimed from PCT/US2001/017443 external-priority patent/WO2002016611A2/fr
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/fr
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2416538A1 publication Critical patent/CA2416538A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions et des méthodes permettant de stimuler ou d'inhiber l'angiogenèse et/ou la vascularisation cardiaque chez les mammifères, notamment les humains. Ces compositions pharmaceutiques renferment des polypeptides ou leurs antagonistes ayant été identifiés pour un ou plusieurs de ces usages. Parmi les troubles pouvant être diagnostiqués, prévenus, ou traités avec ces compositions, on note les traumas tels que les blessures, divers cancers, et les troubles vasculaires, notamment l'athérosclérose et l'hypertrophie cardiaque. Par ailleurs, l'invention concerne de nouveaux polypeptides et des molécules d'acides nucléiques codant ces polypeptides. Cette invention concerne également des vecteurs et des cellules hôtes contenant ces séquences d'acides nucléiques, des molécules de polypeptides chimères contenant les polypeptides de l'invention fusionnés aux séquences de polypeptides hétérologues, des anticorps qui se lient à ces polypeptides, ainsi que des méthodes de production desdits polypeptides.
CA002416538A 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese Abandoned CA2416538A1 (fr)

Applications Claiming Priority (73)

Application Number Priority Date Filing Date Title
US21955600P 2000-07-20 2000-07-20
US60/219,556 2000-07-20
US22066400P 2000-07-25 2000-07-25
US22062400P 2000-07-25 2000-07-25
US60/220,624 2000-07-25
US60/220,664 2000-07-25
USPCT/US00/20710 2000-07-28
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
US22269500P 2000-08-02 2000-08-02
US60/222,695 2000-08-02
US09/643,657 US6642024B1 (en) 1998-01-29 2000-08-17 Guanylate-binding protein
US09/643,657 2000-08-17
PCT/US2000/023522 WO2001016319A2 (fr) 1999-08-31 2000-08-23 Compositions et procedes pour le traitement de maladies d'ordre immunologique
USPCT/US00/23522 2000-08-23
USPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US23097800P 2000-09-07 2000-09-07
US60/230,978 2000-09-07
US60/000,000 2000-09-15
US66535000A 2000-09-18 2000-09-18
US66461000A 2000-09-18 2000-09-18
US09/664,610 2000-09-18
US09/665,350 2000-09-18
US24292200P 2000-10-24 2000-10-24
US60/242,922 2000-10-24
US70923800A 2000-11-08 2000-11-08
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
US09/709,238 2000-11-08
USPCT/US00/30952 2000-11-08
PCT/US2000/030873 WO2001040465A2 (fr) 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique
USPCT/US00/30873 2000-11-10
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/32678 2000-12-01
US09/747,259 US6569645B2 (en) 1999-05-14 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
US09/747,259 2000-12-20
USPCT/US00/34956 2000-12-20
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
US09/767,609 US20020042367A1 (en) 1997-11-25 2001-01-22 Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US09/767,609 2001-01-22
US79649801A 2001-02-28 2001-02-28
US09/796,498 2001-02-28
PCT/US2001/006520 WO2001068848A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US01/06520 2001-02-28
PCT/US2001/006666 WO2001066740A2 (fr) 2000-03-03 2001-03-01 Compositions et methodes de traitement de maladies d'origine immune
USPCT/US01/06666 2001-03-01
US80270601A 2001-03-09 2001-03-09
US09/802,706 2001-03-09
US80868901A 2001-03-14 2001-03-14
US09/808,689 2001-03-14
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US09/816,744 2001-03-22
US09/828,366 US20020010137A1 (en) 1997-09-18 2001-04-05 Methods and compositions for inhibiting neoplastic cell growth
US09/828,366 2001-04-05
US09/854,208 US7217412B2 (en) 1998-05-15 2001-05-10 IL-17C related mammalian cytokine polypeptides
US09/854,280 2001-05-10
US09/854,208 2001-05-10
US09/854,280 US7115398B2 (en) 1998-05-15 2001-05-10 IL-17 homologous polypeptides and therapeutic uses thereof
US09/866,034 2001-05-25
USPCT/US01/17092 2001-05-25
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
PCT/US2001/017092 WO2001092331A2 (fr) 2000-05-30 2001-05-25 Compositions et methodes de traitement de maladies d'origine immune
US09/866,034 US20030170864A1 (en) 2000-05-30 2001-05-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/866,028 2001-05-25
US09/870,574 US6551799B2 (en) 1999-12-07 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
USPCT/US01/17443 2001-05-30
US09/870,574 2001-05-30
PCT/US2001/017443 WO2002016611A2 (fr) 2000-08-24 2001-05-30 Polypeptides d'interleukine-22, acides nucleiques codant pour lesdits polypeptides et methode permettant de traiter les affections pancreatiques
USPCT/US01/17800 2001-06-01
PCT/US2001/017800 WO2001093983A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
USPCT/US01/19692 2001-06-20
PCT/US2001/019692 WO2002000690A2 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
USPCT/US01/00000 2001-06-28
PCT/US2001/021735 WO2002008284A2 (fr) 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese

Publications (1)

Publication Number Publication Date
CA2416538A1 true CA2416538A1 (fr) 2002-01-31

Family

ID=56290165

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002416538A Abandoned CA2416538A1 (fr) 2000-07-20 2001-07-09 Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese

Country Status (5)

Country Link
EP (1) EP1309685A2 (fr)
JP (5) JP2004516013A (fr)
AU (1) AU2001271973A1 (fr)
CA (1) CA2416538A1 (fr)
WO (1) WO2002008284A2 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000690A2 (fr) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
WO1999012963A2 (fr) 1997-09-12 1999-03-18 Biogen, Inc. Recepteurs 'trail' riches en cysteine
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US7109292B2 (en) 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119113A1 (en) 1999-07-20 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001012811A1 (fr) 1999-08-12 2001-02-22 Urogenesys, Inc. Antigene transmembranaire lectine du type c exprime dans le cancer humain de la prostate et ses utilisations
EP1623991A3 (fr) * 1999-09-01 2006-06-07 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
JP3964678B2 (ja) 1999-10-28 2007-08-22 アジェンシス，インコーポレイテッド ３６ｐ６ｄ５：分泌腫瘍抗原
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030158382A1 (en) * 2000-04-21 2003-08-21 Nobutaka Wakamiya Novel collectins
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2275549A1 (fr) * 2000-06-23 2011-01-19 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
CA2648048A1 (fr) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
WO2002036625A2 (fr) 2000-11-03 2002-05-10 The Regents Of The University Of California Polypeptides de prokineticine, et methodes et compositions associees
WO2002040654A2 (fr) 2000-11-14 2002-05-23 Bristol-Myers Squibb Company Polynucleotide codant pour une nouvelle serpine humaine (lsi-01) secretee a partir des cellules lymphoides
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
WO2003088808A2 (fr) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
US20060263770A1 (en) * 2002-03-22 2006-11-23 Marco Colonna Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
JPWO2003083114A1 (ja) * 2002-03-28 2005-08-04 アステラス製薬株式会社 アンジオポエチン関連増殖因子
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
AU2003261911A1 (en) * 2002-09-04 2004-03-29 Takeda Pharmaceutical Company Limited Use of disease-associated gene
EP1562587A4 (fr) * 2002-09-11 2006-07-19 Genentech Inc Compositions et methodes pour le traitement de maladies du systeme immunitaire
AU2003279084A1 (en) * 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
PL2784084T5 (pl) 2003-07-08 2024-12-02 Novartis Pharma Ag Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
BRPI0509420A (pt) 2004-04-14 2007-09-04 Genentech Inc método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico
WO2006012232A1 (fr) 2004-06-24 2006-02-02 Mayo Foundation For Medical Education And Research Polypeptide costimulant b7-h5
US7410772B2 (en) 2004-07-02 2008-08-12 Genentech, Inc. Compositions and methods for treatment of non-Hodgkin's lymphoma
CA2576193A1 (fr) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Influence du taj sur les fonctions neuronales
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP3299027A1 (fr) 2005-11-04 2018-03-28 Genentech, Inc. Utilisation d'inhibiteurs de la voie du complément pour traiter les maladies oculaires
CN106188303A (zh) 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
RU2553517C2 (ru) 2008-05-06 2015-06-20 Дженентек, Инк. Варианты crig с созревшей аффинностью
LT2398902T (lt) 2009-02-20 2023-12-27 Astellas Pharma Inc. Vėžio diagnostikos ir gydymo būdai bei kompozicijos
CA2759848C (fr) 2009-05-05 2018-12-04 Novimmune S.A. Anticorps anti-il-17f et leurs methodes d'utilisation
US8404811B2 (en) 2009-05-08 2013-03-26 Genentech, Inc. Humanized anti-EGFL7 antibodies and methods using same
AT508569A1 (de) 2009-07-23 2011-02-15 Affiris Ag Pharmaceutical compound
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
WO2013006486A2 (fr) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, utilisations et procédés pour le traitement de troubles et de maladies métaboliques
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
DK2945642T3 (da) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
WO2015065897A1 (fr) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Modèles de cancer et procédés associés
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
EP3137503A1 (fr) 2014-05-01 2017-03-08 Genentech, Inc. Variants d'anticorps anti-facteur d et leurs utilisations
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (fr) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (fr) 2015-10-30 2017-05-04 Genentech, Inc. Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
EP3503882A4 (fr) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
GB201906052D0 (en) * 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000690A2 (fr) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
WO2000053756A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
CA2302387A1 (fr) * 1997-08-29 1999-03-04 Human Genome Sciences, Inc. 29 proteines humaines secretees
EP1056847A2 (fr) * 1998-02-27 2000-12-06 Sagami Chemical Research Center Proteines humaines possedant des domaines transmembranaires et adn codant ces proteines
JP3868740B2 (ja) * 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
JP2002509722A (ja) * 1998-03-31 2002-04-02 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白およびそれらをコードするポリヌクレオチド
KR20010085792A (ko) * 1998-09-14 2001-09-07 제넨테크, 인크. 혈관형성 및 심혈관형성의 촉진 또는 억제
KR100529270B1 (ko) * 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
AU2399300A (en) * 1999-03-08 2000-09-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
KR100543857B1 (ko) * 1999-09-01 2006-01-23 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제

Also Published As

Publication number Publication date
EP1309685A2 (fr) 2003-05-14
JP2009039117A (ja) 2009-02-26
JP6033531B2 (ja) 2016-11-30
JP2009039119A (ja) 2009-02-26
JP2009039118A (ja) 2009-02-26
AU2001271973A1 (en) 2002-02-05
WO2002008284A2 (fr) 2002-01-31
WO2002008284A3 (fr) 2003-03-13
JP2012005493A (ja) 2012-01-12
JP2004516013A (ja) 2004-06-03

Similar Documents

Publication Publication Date Title
US7135334B2 (en) PRO20044 nucleic acids
JP6033531B2 (ja) 血管形成に関連する障害を診断及び治療するための組成物と方法
US7265210B2 (en) Anti-PRO9821 antibodies
US20040043927A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
CA2412211A1 (fr) Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
US20060074033A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20070191270A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030224984A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20060073558A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2042597A1 (fr) Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
US7332578B2 (en) Anti-pro4407 antibodies
US7238790B2 (en) PRO1313 polypeptides
US20060073556A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2075253A1 (fr) Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
US20060074228A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2015037408A (ja) 血管形成に関連する障害を診断及び治療するための組成物と方法
EP1944317A2 (fr) Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
HK1149590A (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued